newsfilter
← Latest News
GlobeNewswire·

Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder

Phase 2 trial to evaluate reduction in heavy drinking as measured by a change in the World Health Organization drinking risk levels1 Trial is informed by results from Phase 1 studies that showed pharmacokinetic properties of OPNT002 well suited for ��